Iranian Journal of Allergy, Asthma and Immunology 2017. 16(5):370-377.

Effect of Nebulized 3% Hypertonic Saline with Salbutamol on Management of Acute Asthma in Outpatient Adults: A Double-blind, Randomized Clinical Trial in Emergency Department
Arash Forouzan, Kambiz Masoumi, Ali Delirrooyfard, Ali Asgari Darian, Laaya Mokhtar Gandomani


Asthma is one of the most common disorders of respiratory tract, management of which still remains as a serious health problem. This study aimed to compare the efficacy of 3% hypertonic saline (HS) plus salbutamol with solely salbutamol on management of acute adults’ asthma based on peak flow meter findings. In this double-blind randomized clinical trial, 340 adult patients with acute asthma attacks admitted to emergency department of Ahvaz Golestan and Emam hospitals were enrolled during 2014-2015. The patients were allocated randomly to intervention group (nebulized 2.5 mg of salbutamol and 2.5 mL of 3% HS solution for three consecutive 20-min periods) and control group (nebulized only salbutamol in the same dose and time of the intervention group). The principal outcome measures were forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR), which were assessed at baseline, and 20, 40 and 60 minutes after treatment in both groups. HS plus salbutamol resulted in a significant increase compared with solely salbutamol in both PEFR and FEV1 in 40th min (0.11±1.36; p=0.036 and 0.05±1.16; p=0.033, respectively) and 60th min (0.15±1.12; p<0.001 and 0.11±1.22; p=0.011, respectively), while no significant difference was observed in baseline and 20th min. Also, PEFR and FEV1 in both groups significantly increased as the treatment processed and the time passed. The results showed the beneficial effects of 3% HS in management of adults with acute asthma in the short term.


Acute asthma; Emergency department; Hypertonic saline; Salbutamol

Full Text:



  1. Kaur BP, Lahewala S, Arora S, Agnihotri K, Panaich SS, Secord E, et al. Asthma: Hospitalization trends and predictors of in-hospital mortality and hospitalization costs in the USA (2001-2010). Int Arch Allergy Immunol 2015; 168(2):71-8.
  2. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol 2015; 5(Suppl 1):S7-10.
  3. Loftus PA, Wise SK. Epidemiology of asthma. Curr Opin Otolaryngol Head Neck Surg 2016; 24(3):245-9.
  4. Varmaghani M, Farzadfar F, Sharifi F, Rashidian A, Moin M, Moradi-Lakeh M, et al. Prevalence of asthma, COPD, and chronic bronchitis in Iran: A systematic review and meta-analysis. Iran J Allergy Asthma Immunol 2016; 15(2):93-104.
  5. Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, risk factors, and mechanisms of adult-onset asthma. Mediators Inflamm 2015; 2015:514868.
  6. Lommatzsch M, Stoll P. Novel strategies for the treatment of asthma. Allergo J Int 2016; 25:11-17.
  7. Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clin Rev Allergy Immunol 2015; 48(1):114-25.
  8. Kew KM, Quinn M, Quon BS, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2016; 6:CD007524.
  9. Olveira C, Muñoz A, Domenech A. Nebulized therapy. SEPAR year. Arch Bronconeumol 2014; 50(12):535-45.
  10. Taube C, Holz O, Mücke M, Jörres RA, Magnussen H. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(10):1810-5.
  11. Dentice RL, Elkins MR, Middleton PG, Bishop JR, Wark PA, Dorahy DJ, et al. A randomized trial of hypertonic saline during hospitalization for exacerbation of cystic fibrosis. Thorax 2016; 71(2):141-7.
  12. Reeves EP, McCarthy C, McElvaney OJ, Vijayan MS, White MM, Dunlea DM, et al. Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signaling and function. World J Crit Care Med 2015; 4(3):179-91.
  13. Baron J, El-Chaar G. Hypertonic saline for the treatment of bronchiolitis in infants and young children: A critical review of the literature. J Pediatr Pharmacol Ther 2016; 21(1):7-26.
  14. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. BMC Pulm Med 2015; 15:148.
  15. Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: An updated meta-analysis. Pediatr Neonatol 2014; 55(6):431-8.
  16. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: A systematic review. Pediatrics 2015; 136(4):687-701.
  17. James DR, Lyttle MD. British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014. Arch Dis Child Educ Pract Ed 2016; 101(6):319-22.
  18. Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, Tukiainen HO. Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 2008; 38(7):1100-7.
  19. Purokivi M, Koskela H, Kontra K. Determinants of asthma control and quality of life in stable asthma: evaluation of two new cough provocation tests. Clin Respir J 2013; 7(3):253-60.
  20. Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP, et al. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J 1996; 9(4):725-32.
  21. Alexis NE, Bennett WD, Peden DB. Safety and Benefits of Inhaled Hypertonic Saline Following Airway Challenges with Endotoxin and Allergen in Asthmatics. J Asthma 2017; In press.
  22. Boon M, Jorissen M, Jaspers M, Augustijns P, Vermeulen FL, Proesmans M, et al. The Influence of Nebulized Drugs on Nasal Ciliary Activity. J Aerosol Med Pulm Drug De liv 2016; 29(4):378-85.
  23. Puebla MJ, Olaguibel JM, Almudevar E, Echegoyen AA, Vela C, de Esteban B. Mannitol versus hypertonic saline: Safety and efficacy of mannitol and hypertonic saline in sputum induction and bronchial hyperreactivity assessment. Chron Respir Dis 2015; 12(3):197-203.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.